中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Viral Diseases NASH/PBC Cancer Exploratory Indications
  • Products&Pipeline
    Pipeline Products Clinical Trials
  • Partnership
  • Investors
    Financials & Filing Presentation Materials
  • News
  • Careers
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • Ascletis and Roche Enter Exclusive Pegasys Partnership in China for Viral Hepatitis

    2018-11-20

  • Ascletis Appoints Dr. Lindi Tan as Chief Financial Officer

    2018-11-12

  • Ascletis to Present Phase II / III Clinical Study for Its Innovative All-oral HCV Treatment at the 69th Annual meeting of AASLD

    2018-11-06

  • Ascletis' Ravidasvir NDA Proposed for Priority Review by the CFDA

    2018-10-18

  • Ascletis' Ganovo is Eligible for Shaoxing Government Funding Subsidy Program to Treat HCV Patients

    2018-10-15

  • Ganovo® Enrolled in the Basic Medical Insurance of Tianjin--Capped Reimbursement-Per-Patient Pilot Program

    2018-09-26

  • Ascletis Invited to attend the Summer Davos Forum Tianjin 2018

    2018-09-17

  • Ascletis’ NDA for Its All-oral HCV Treatment Accepted by CFDA

    2018-08-01

  • Ascletis Filed NDA for Its All-oral HCV Treatment

    2018-07-31

  • Ganovo® Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association

    2018-07-30

 
  • 1
  • 2
  •  
  • »
    • © 2018 Ascletis Pharma Inc.
    • 浙公网安备 33010802003344号
    • All Rights Reserved
    • 浙ICP备 11050387号-1

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备11050387号-1